Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Cardiovascular risk
HIV
Lipid
Tenofovir alafenamide
Weight gain
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Sep 2021
06 Sep 2021
Historique:
received:
02
02
2021
accepted:
19
07
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens. For this retrospective study, we selected HIV-infected patients with suppressed viral load who fitted in one of the two groups below: First group (TDF/TDF): Patients treated continuously with TDF-based regimens. Second group (TDF/TAF): Patients treated with TDF-regimens during at least 6 months then switched to TAF-regimens while maintaining other drugs unchanged. Available data included date of birth, gender, ethnicity, lymphocyte T CD4 Switching from TDF to TAF resulted in a significant increase in triglycerides levels, total cholesterol and HDL cholesterol. LDL cholesterol and total cholesterol/HDL ratio did not show significant changes. Calculated cardiovascular risk increased after switch from TDF- to TAF-based therapy. Together with favorable outcomes at the bone and kidney levels, potential negative impact of TAF on lipid profile should be included in the reflection to propose the most appropriate and tailored ARV treatment.
Sections du résumé
BACKGROUND
BACKGROUND
As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens.
METHODS
METHODS
For this retrospective study, we selected HIV-infected patients with suppressed viral load who fitted in one of the two groups below: First group (TDF/TDF): Patients treated continuously with TDF-based regimens. Second group (TDF/TAF): Patients treated with TDF-regimens during at least 6 months then switched to TAF-regimens while maintaining other drugs unchanged. Available data included date of birth, gender, ethnicity, lymphocyte T CD4
RESULTS
RESULTS
Switching from TDF to TAF resulted in a significant increase in triglycerides levels, total cholesterol and HDL cholesterol. LDL cholesterol and total cholesterol/HDL ratio did not show significant changes. Calculated cardiovascular risk increased after switch from TDF- to TAF-based therapy.
CONCLUSIONS
CONCLUSIONS
Together with favorable outcomes at the bone and kidney levels, potential negative impact of TAF on lipid profile should be included in the reflection to propose the most appropriate and tailored ARV treatment.
Identifiants
pubmed: 34488664
doi: 10.1186/s12879-021-06479-9
pii: 10.1186/s12879-021-06479-9
pmc: PMC8420041
doi:
Substances chimiques
Anti-HIV Agents
0
Lipids
0
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
910Informations de copyright
© 2021. The Author(s).
Références
PLoS One. 2017 Oct 19;12(10):e0185761
pubmed: 29049344
N Engl J Med. 2007 Apr 26;356(17):1723-35
pubmed: 17460226
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
N Engl J Med. 2019 Aug 29;381(9):816-826
pubmed: 31339676
Clin Infect Dis. 2020 Sep 12;71(6):1390-1392
pubmed: 31608360
Lancet HIV. 2016 Nov;3(11):e510-e520
pubmed: 27658869
Clin Infect Dis. 2003 Jul 15;37(2):292-8
pubmed: 12856222
AIDS Res Hum Retroviruses. 2016 Jan;32(1):50-8
pubmed: 26352511
Nat Rev Dis Primers. 2020 Jun 18;6(1):48
pubmed: 32555389
Clin Infect Dis. 2007 Oct 15;45(8):1074-81
pubmed: 17879928
Am J Med. 1989 Jan;86(1):27-31
pubmed: 2910092
J Am Heart Assoc. 2017 Apr 24;6(4):
pubmed: 28438737
J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34
pubmed: 16878047
BMC Infect Dis. 2017 Aug 9;17(1):551
pubmed: 28793863
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501
pubmed: 20543702
AIDS. 2010 Jun 19;24(10):1537-48
pubmed: 20453631
Healthcare (Basel). 2018 Feb 14;6(1):
pubmed: 29443936
Clin Infect Dis. 2016 Oct 15;63(8):1122-1129
pubmed: 27444412
AIDS. 2019 Dec 1;33(15):2387-2391
pubmed: 31764103
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):245-53
pubmed: 21499115
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31818822
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218
pubmed: 28282300
Clin Infect Dis. 2011 Dec;53(11):1120-6
pubmed: 21998278
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55
pubmed: 23807155
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389
pubmed: 31606734
J Chemother. 2017 Oct;29(5):299-307
pubmed: 28019192
Rev Assoc Med Bras (1992). 2013 Mar-Apr;59(2):186-98
pubmed: 23582562
Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479-490
pubmed: 30388308
AIDS. 2020 Jul 1;34(8):1161-1170
pubmed: 32310899
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
Curr Opin HIV AIDS. 2017 Jul;12(4):324-333
pubmed: 28403027
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70
pubmed: 20700060
AIDS. 2010 Jul 17;24(11):1781-4
pubmed: 20495438